# US 8,541,007 B2 · Vaccines against chlamydial infection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,541,007 B2
- Document ID: US8541007B2
- Status: Granted
- Kind: B2
- Application number: 12/974,428
- Filed: 2010-12-21
- Published: 2011-12-08
- Granted: 2013-09-24
- Earliest claimed: 2005-03-31
- Assignees: Glaxosmithkline Biologicals SA; Corixa Corporation
- Applicants: Mark Alderson; Ajay Bhatia; Yves Lobet; Brenda Maisonneuve; Jean-Francois L Maisonneuve; Martine Marchand; Pascal Mettens; Florence Bernadette Nozay; Peter Probst; Samira H Skeiky
- Inventors: Mark Alderson; Ajay Bhatia; Yves Lobet; Brenda Maisonneuve; Jean-Francois L Maisonneuve; Martine Marchand; Pascal Mettens; Florence Bernadette Nozay; Peter Probst; Yasir A Skeiky
- Web page: https://patentgrep.com/patent/US8541007B2

## CPC

- A61K 39/118: Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci
- A61P 31/04: Antibacterial agents
- G01N 33/56927: {Chlamydia}
- A61K 2039/55555: {Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers}
- A61K 2039/55572: {Lipopolysaccharides; Lipid A; Monophosphoryl lipid A}
- A61K 2039/55577: {Saponins; Quil A; QS21; ISCOMS}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates to compositions comprising proteins or polynucleotides of Chlamydia sp., in particular combinations of proteins or polynucleotides encoding them, and methods for the use of the proteins or polynucleotides in the treatment, prevention and diagnosis of Chlamydia infection.

## Claims

### Claim 1

A composition comprising:
(i) an isolated Ct-858 Chlamydia protein consisting of SEQ ID NO: 6;
(ii) an isolated Ct-089 Chlamydia protein consisting of SEQ ID NO:16; and
(iii) a pharmaceutically acceptable carrier.

### Claim 2 (depends on 1)

A composition according to claim 1 which comprises a Chlamydia Ct-089 protein.

### Claim 3 (depends on 2)

A composition according to claim 2 further comprising a Chlamydia Ct-875 protein or immunogenic fragment thereof.

### Claim 4 (depends on 3)

A composition according to claim 3 further comprising a Chlamydia PmpDpd protein or an immunogenic fragment thereof.

### Claim 5 (depends on 1)

A composition according to claim 1, wherein the composition is an immunogenic composition.

### Claim 6 (depends on 5)

A composition according to claim 5 further comprising adjuvant.

### Claim 7 (depends on 6)

A composition according to claim 6 wherein the adjuvant is a preferential stimulator of a Th1 response.

### Claim 8 (depends on 7)

A composition according to claim 7 wherein the adjuvant comprises 3D-MPL, QS21 or a combination of 3D-MPL and QS21.

### Claim 9 (depends on 8)

A composition according to claim 8 wherein the adjuvant further comprises an oil in water emulsion.

### Claim 10 (depends on 8)

A composition according to claim 8 wherein the adjuvant further comprises liposomes.

### Claim 11 (depends on 1)

A composition according to claim 1 wherein said isolated Chlamydia proteins are linked to form a fusion protein.

### Claim 12

A composition comprising a polypeptide consisting of SEQ ID NO:6, a polypeptide consisting of SEQ ID NO:16, and an isolated Chlamydia polypeptide selected from:
Ct-875, PmpD passenger domain, and PmpG passenger domain.

### Claim 13 (depends on 12)

A composition according to claim 12, wherein:
(a) Ct-875 is a polypeptide having at least 95% sequence identity to SEQ ID NO. 8;
(b) PmpD passenger domain is a polypeptide having at least 95% sequence identity to SEQ ID NO. 14; and
(e) PmpG passenger domain is a polypeptide having at least 95% sequence identity to SEQ ID NO 12.

### Claim 14 (depends on 12)

A composition according to claim 12 wherein all of said Chlamydia polypeptides are from Chlamydia trachomatis.